[
  {
    "title": "可更好预防变异株！康希诺新冠mRNA疫苗新进展…",
    "href": "http://stock.jrj.com.cn/2023/01/06125437263776.shtml",
    "datetime": "2023-01-06 12:54:03",
    "code": "688185"
  },
  {
    "title": "新进展！康希诺新冠mRNA疫苗临床研究取得积极阶段性数据，可更好预防变异株",
    "href": "http://stock.jrj.com.cn/2023/01/06083637263029.shtml",
    "datetime": "2023-01-06 08:36:06",
    "code": "688185"
  },
  {
    "title": "晚间公告全知道：康希诺称新冠疫苗CS-2034不良反应发生率及严重程度显著低于文献报道的已上市mRNA疫苗",
    "href": "http://stock.jrj.com.cn/2023/01/05205137262445.shtml",
    "datetime": "2023-01-05 20:51:03",
    "code": "688185"
  },
  {
    "title": "康希诺：新冠疫苗CS-2034近期一项序贯加强临床研究取得积极阶段性数据",
    "href": "http://stock.jrj.com.cn/2023/01/05192737262208.shtml",
    "datetime": "2023-01-05 19:27:39",
    "code": "688185"
  },
  {
    "title": "科兴、康希诺、君实生物…新冠药巨头突然集体现身，有何深意？",
    "href": "http://stock.jrj.com.cn/2023/01/05080937260122.shtml",
    "datetime": "2023-01-05 08:09:05",
    "code": "688185"
  },
  {
    "title": "华兰股份：新冠疫苗用胶塞客户有康希诺、神州细胞等",
    "href": "http://stock.jrj.com.cn/2022/12/29194837247421.shtml",
    "datetime": "2022-12-29 19:48:15",
    "code": "688185"
  },
  {
    "title": "康希诺AH股走高 3剂灭活疫苗人群加强接种吸入用新冠疫苗 安全性良好",
    "href": "http://stock.jrj.com.cn/2022/12/29093437245272.shtml",
    "datetime": "2022-12-29 09:34:48",
    "code": "688185"
  },
  {
    "title": "晚间公告全知道：中国交建分拆下属三家设计院重组上市 康希诺公布吸入用及肌注式新冠疫苗近期临床研究成果",
    "href": "http://stock.jrj.com.cn/2022/12/28210637244385.shtml",
    "datetime": "2022-12-28 21:06:38",
    "code": "688185"
  },
  {
    "title": "【公告精选】华夏幸福：拟向华润置地转让下属公司124亿元股权及债权；康希诺：公布吸入用及肌注式新冠疫",
    "href": "http://stock.jrj.com.cn/2022/12/28210037244374.shtml",
    "datetime": "2022-12-28 21:00:09",
    "code": "688185"
  },
  {
    "title": "康希诺：公布吸入用新冠疫苗及肌注式新冠疫苗近期临床研究成果",
    "href": "http://stock.jrj.com.cn/2022/12/28171437243466.shtml",
    "datetime": "2022-12-28 17:14:45",
    "code": "688185"
  },
  {
    "title": "疫苗股震荡走弱 康希诺领跌",
    "href": "http://stock.jrj.com.cn/2022/12/19103237221715.shtml",
    "datetime": "2022-12-19 10:32:55",
    "code": "688185"
  },
  {
    "title": "康希诺：肌注式及吸入用新冠疫苗被推荐作为第二剂次加强免疫接种",
    "href": "http://stock.jrj.com.cn/2022/12/14164137212124.shtml",
    "datetime": "2022-12-14 16:41:56",
    "code": "688185"
  },
  {
    "title": "康希诺AH齐涨 将按需求供应新冠疫苗",
    "href": "http://stock.jrj.com.cn/2022/12/14141437211643.shtml",
    "datetime": "2022-12-14 14:14:42",
    "code": "688185"
  },
  {
    "title": "医药股大分化，以岭药业跌停，康希诺涨超10％",
    "href": "http://stock.jrj.com.cn/2022/12/14133437211565.shtml",
    "datetime": "2022-12-14 13:34:03",
    "code": "688185"
  },
  {
    "title": "A股康希诺拉升涨近3% 港股康希诺生物直线拉升超5%",
    "href": "http://stock.jrj.com.cn/2022/12/14102737211099.shtml",
    "datetime": "2022-12-14 10:27:04",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟使用剩余超募资金约11.89亿元永久补充流动资金",
    "href": "http://stock.jrj.com.cn/2022/12/02192837185464.shtml",
    "datetime": "2022-12-02 19:28:14",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：完成股份回购、已实际回购68.3748万股",
    "href": "http://stock.jrj.com.cn/2022/12/02192737185472.shtml",
    "datetime": "2022-12-02 19:27:00",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：截至11月底已累计回购67.01万股A股",
    "href": "http://stock.jrj.com.cn/2022/12/01175537182082.shtml",
    "datetime": "2022-12-01 17:55:26",
    "code": "688185"
  },
  {
    "title": "快讯：疫苗概念股尾盘拉升，康希诺涨超12%",
    "href": "http://stock.jrj.com.cn/invest/2022/11/29145837174179.shtml",
    "datetime": "2022-11-29 14:58:17",
    "code": "688185"
  },
  {
    "title": "落袋为安！暴涨的康希诺H股遭摩根大通减持",
    "href": "http://stock.jrj.com.cn/2022/11/29105337173490.shtml",
    "datetime": "2022-11-29 10:53:15",
    "code": "688185"
  },
  {
    "title": "康希诺生物AH齐跌 遭摩根大通减持107.09万股",
    "href": "http://stock.jrj.com.cn/2022/11/28111937170260.shtml",
    "datetime": "2022-11-28 11:19:25",
    "code": "688185"
  },
  {
    "title": "康希诺：吸入用新冠疫苗已公开接种点数量超1000个",
    "href": "http://stock.jrj.com.cn/2022/11/23170037160985.shtml",
    "datetime": "2022-11-23 17:00:22",
    "code": "688185"
  },
  {
    "title": "又一地！康希诺吸入式新冠疫苗将落地北京，沪上体验者称其“接种便利”打动人",
    "href": "http://stock.jrj.com.cn/2022/11/16072137142165.shtml",
    "datetime": "2022-11-16 07:21:05",
    "code": "688185"
  },
  {
    "title": "康希诺跌超15%振幅超30% 康希诺生物振幅超37%",
    "href": "http://stock.jrj.com.cn/2022/11/11143537130942.shtml",
    "datetime": "2022-11-11 14:35:01",
    "code": "688185"
  },
  {
    "title": "新冠药板块跳水，康希诺翻绿，众生药业炸板",
    "href": "http://stock.jrj.com.cn/2022/11/11141837130894.shtml",
    "datetime": "2022-11-11 14:18:25",
    "code": "688185"
  },
  {
    "title": "康希诺AH股均涨超10% 吸入用新冠疫苗获得摩洛哥紧急使用许可",
    "href": "http://stock.jrj.com.cn/2022/11/11093037130006.shtml",
    "datetime": "2022-11-11 09:30:46",
    "code": "688185"
  },
  {
    "title": "火上浇油！疫苗巨头又发重磅利好，股价半个月已大涨一倍",
    "href": "http://stock.jrj.com.cn/2022/11/11081337129746.shtml",
    "datetime": "2022-11-11 08:13:10",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：吸入用重组新型冠状病毒疫苗(5型腺病毒载体)获得摩洛哥紧急使用许可",
    "href": "http://stock.jrj.com.cn/2022/11/10183137128475.shtml",
    "datetime": "2022-11-10 18:31:12",
    "code": "688185"
  },
  {
    "title": "康希诺：吸入用新冠疫苗获得摩洛哥紧急使用许可",
    "href": "http://stock.jrj.com.cn/2022/11/10182837128417.shtml",
    "datetime": "2022-11-10 18:28:55",
    "code": "688185"
  },
  {
    "title": "康希诺AH股早盘双双大涨！吸入用新冠疫苗在天津开启接种；跨界光伏被问询，这只股票早盘依然涨停，股价创",
    "href": "http://stock.jrj.com.cn/2022/11/10125537127069.shtml",
    "datetime": "2022-11-10 12:55:00",
    "code": "688185"
  },
  {
    "title": "暴涨2倍！440亿疫苗龙头遭股东七度减持，什么情况？资金却在密集布局医药股",
    "href": "http://stock.jrj.com.cn/2022/11/08081037119018.shtml",
    "datetime": "2022-11-08 08:10:15",
    "code": "688185"
  },
  {
    "title": "康希诺A股涨超7%，10个交易日股价已翻倍",
    "href": "http://stock.jrj.com.cn/2022/11/07102137116135.shtml",
    "datetime": "2022-11-07 10:21:24",
    "code": "688185"
  },
  {
    "title": "康希诺AH股齐涨 吸入式新冠疫苗已在全国全面铺开使用",
    "href": "http://stock.jrj.com.cn/2022/11/07094037116043.shtml",
    "datetime": "2022-11-07 09:40:08",
    "code": "688185"
  },
  {
    "title": "连续4涨停！供销社多股涨嗨了！沪指盘中失守3000点，疫苗巨头康希诺跌超30%，啥情况？",
    "href": "http://stock.jrj.com.cn/invest/2022/11/03132337109286.shtml",
    "datetime": "2022-11-03 13:23:47",
    "code": "688185"
  },
  {
    "title": "康希诺生物跌近30%，康希诺跌近10%，公司称预期吸入式疫苗不会带来业绩大幅增长",
    "href": "http://stock.jrj.com.cn/2022/11/03093637108687.shtml",
    "datetime": "2022-11-03 09:36:17",
    "code": "688185"
  },
  {
    "title": "康希诺AH暴涨后大跌 强调预期吸入用新冠疫苗不会带来公司业绩的大幅增长",
    "href": "http://stock.jrj.com.cn/2022/11/03093337108700.shtml",
    "datetime": "2022-11-03 09:33:37",
    "code": "688185"
  },
  {
    "title": "7天股价翻倍！多地推广“第四针”，康希诺回应：预期吸入式疫苗不会带来业绩大幅增长",
    "href": "http://stock.jrj.com.cn/2022/11/03082837108508.shtml",
    "datetime": "2022-11-03 08:28:40",
    "code": "688185"
  },
  {
    "title": "多地推广“第四针”计划，康希诺股价大涨！产能是否跟得上？公司回应了",
    "href": "http://stock.jrj.com.cn/2022/11/02223437108106.shtml",
    "datetime": "2022-11-02 22:34:30",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：预期吸入用新冠疫苗不会带来公司业绩的大幅增长、提醒避免跟风炒作",
    "href": "http://stock.jrj.com.cn/2022/11/02214837108033.shtml",
    "datetime": "2022-11-02 21:48:38",
    "code": "688185"
  },
  {
    "title": "疫苗概念大涨！康希诺港股单日爆拉63% 供销社板块多股连板 会成为下一个主线？",
    "href": "http://stock.jrj.com.cn/2022/11/02205237107873.shtml",
    "datetime": "2022-11-02 20:52:10",
    "code": "688185"
  },
  {
    "title": "龙虎榜：众机构锁仓康希诺，大港股份被砸“天地板”",
    "href": "http://stock.jrj.com.cn/hotstock/2022/11/02181237107281.shtml",
    "datetime": "2022-11-02 18:12:54",
    "code": "688185"
  },
  {
    "title": "康希诺：对吸入用新冠疫苗的大规模使用进行了提前布局",
    "href": "http://stock.jrj.com.cn/2022/11/02175037107167.shtml",
    "datetime": "2022-11-02 17:50:13",
    "code": "688185"
  },
  {
    "title": "康希诺今日涨停 两机构买入9554万元",
    "href": "http://stock.jrj.com.cn/2022/11/02170037106890.shtml",
    "datetime": "2022-11-02 17:00:31",
    "code": "688185"
  },
  {
    "title": "携手腾讯，中国联通直拉涨停！沪指重上3000点，旅游、免税板块大幅上涨，康希诺港股盘中暴涨70%",
    "href": "http://stock.jrj.com.cn/2022/11/02151437106391.shtml",
    "datetime": "2022-11-02 15:14:11",
    "code": "688185"
  },
  {
    "title": "刚刚，一条大消息，疫苗巨头狂拉60%！“供销社”彻底火了，多股连续涨停！",
    "href": "http://stock.jrj.com.cn/2022/11/02123737105967.shtml",
    "datetime": "2022-11-02 12:37:55",
    "code": "688185"
  },
  {
    "title": "刚刚！易纲重磅发声，人民币币值和购买力将保持稳定！A股港股再度大涨，康希诺狂飙50%！这些板块嗨了",
    "href": "http://stock.jrj.com.cn/2022/11/02114237105799.shtml",
    "datetime": "2022-11-02 11:42:15",
    "code": "688185"
  },
  {
    "title": "康希诺20%涨停，7日股价累计涨超96%",
    "href": "http://stock.jrj.com.cn/2022/11/02101437105531.shtml",
    "datetime": "2022-11-02 10:14:30",
    "code": "688185"
  },
  {
    "title": "新冠药概念异动冲高，康希诺20%涨停",
    "href": "http://stock.jrj.com.cn/2022/11/02100837105519.shtml",
    "datetime": "2022-11-02 10:08:10",
    "code": "688185"
  },
  {
    "title": "康希诺A股涨停 H股暴涨超40%",
    "href": "http://stock.jrj.com.cn/2022/11/02095537105506.shtml",
    "datetime": "2022-11-02 09:55:16",
    "code": "688185"
  },
  {
    "title": "康希诺AH股大涨 吸入用新冠疫苗在江苏十三个城市陆续开启接种",
    "href": "http://stock.jrj.com.cn/2022/11/02093637105435.shtml",
    "datetime": "2022-11-02 09:36:00",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：截至10月底累计回购50万股A股",
    "href": "http://stock.jrj.com.cn/2022/11/01165637103611.shtml",
    "datetime": "2022-11-01 16:56:55",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺AH股继续拉升 H股7日累计涨幅达80%",
    "href": "http://stock.jrj.com.cn/2022/11/01144537102966.shtml",
    "datetime": "2022-11-01 14:45:55",
    "code": "688185"
  },
  {
    "title": "康希诺AH股低开 前三季度归母净亏损扩大135%",
    "href": "http://stock.jrj.com.cn/2022/10/31092937098496.shtml",
    "datetime": "2022-10-31 09:29:58",
    "code": "688185"
  },
  {
    "title": "本周十大牛熊股：信创成牛股摇篮，吸入式新冠疫苗引爆康希诺",
    "href": "http://stock.jrj.com.cn/2022/10/30231937097979.shtml",
    "datetime": "2022-10-30 23:19:47",
    "code": "688185"
  },
  {
    "title": "康希诺AH股持续走强 连涨5日 机构称吸入式新冠疫苗料逐渐成主流",
    "href": "http://stock.jrj.com.cn/2022/10/28120137093175.shtml",
    "datetime": "2022-10-28 12:01:37",
    "code": "688185"
  },
  {
    "title": "“吸入式”新冠疫苗刷屏，谁能为康希诺的“新故事”买单？",
    "href": "http://stock.jrj.com.cn/2022/10/28081437092365.shtml",
    "datetime": "2022-10-28 08:14:45",
    "code": "688185"
  },
  {
    "title": "疫苗概念大涨，康希诺涨停",
    "href": "http://stock.jrj.com.cn/2022/10/26110237084828.shtml",
    "datetime": "2022-10-26 11:02:06",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟参设合伙企业天津千汐",
    "href": "http://stock.jrj.com.cn/2022/09/29171537031379.shtml",
    "datetime": "2022-09-29 17:15:51",
    "code": "688185"
  },
  {
    "title": "惊！西北工业大学遭网络攻击，源头竟是美国国家安全局！传统能源股开盘走强；一纸公告，康希诺AH股双双高",
    "href": "http://stock.jrj.com.cn/2022/09/05131736973321.shtml",
    "datetime": "2022-09-05 13:17:20",
    "code": "688185"
  },
  {
    "title": "康希诺AH股联袂大涨！全球首款吸入用新冠疫苗获批紧急使用",
    "href": "http://stock.jrj.com.cn/2022/09/05103536972851.shtml",
    "datetime": "2022-09-05 10:35:16",
    "code": "688185"
  },
  {
    "title": "康希诺AH股大幅高开 吸入用重组新型冠状病毒疫苗作为加强针在中国被纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2022/09/05092636972563.shtml",
    "datetime": "2022-09-05 09:26:52",
    "code": "688185"
  },
  {
    "title": "全球首款！获准紧急使用",
    "href": "http://stock.jrj.com.cn/2022/09/05063736972242.shtml",
    "datetime": "2022-09-05 06:37:00",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：吸入用重组新型冠状病毒疫苗(5型腺病毒载体)作为加强针被纳入紧急使用",
    "href": "http://stock.jrj.com.cn/2022/09/04160936971908.shtml",
    "datetime": "2022-09-04 16:09:25",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：截至8月底已累计回购50万股A股",
    "href": "http://stock.jrj.com.cn/2022/08/31155936958115.shtml",
    "datetime": "2022-08-31 15:59:12",
    "code": "688185"
  },
  {
    "title": "康希诺生物(06185.HK)遭The Capital Group减持34.19万股",
    "href": "http://stock.jrj.com.cn/2022/08/31075036955947.shtml",
    "datetime": "2022-08-31 07:50:37",
    "code": "688185"
  },
  {
    "title": "新冠疫苗赛道降温后的角逐战，康希诺继续“死磕”",
    "href": "http://stock.jrj.com.cn/2022/08/29203936948920.shtml",
    "datetime": "2022-08-29 20:39:15",
    "code": "688185"
  },
  {
    "title": "暴跌99%！300亿疫苗巨头突然爆雷，超8成机构已撤退",
    "href": "http://stock.jrj.com.cn/2022/08/29190636948477.shtml",
    "datetime": "2022-08-29 19:06:20",
    "code": "688185"
  },
  {
    "title": "康希诺未来发力点在哪？",
    "href": "http://stock.jrj.com.cn/2022/08/29171636947748.shtml",
    "datetime": "2022-08-29 17:16:35",
    "code": "688185"
  },
  {
    "title": "康希诺H股跌超11%，2022年上半年营利同比双降",
    "href": "http://stock.jrj.com.cn/2022/08/29102636945998.shtml",
    "datetime": "2022-08-29 10:26:07",
    "code": "688185"
  },
  {
    "title": "上半年净利同比下降98%，康希诺股价重挫逾15%，康希诺生物跌超14%",
    "href": "http://stock.jrj.com.cn/2022/08/29095936945794.shtml",
    "datetime": "2022-08-29 09:59:15",
    "code": "688185"
  },
  {
    "title": "康希诺披露2022年半年报 实现营收6.30亿元",
    "href": "http://stock.jrj.com.cn/2022/08/29092936945558.shtml",
    "datetime": "2022-08-29 09:29:14",
    "code": "688185"
  },
  {
    "title": "隐形重仓股来了！明星基金经理买了这些股票；“三桶油”业绩大爆发，日赚近11亿；疫苗巨头康希诺业绩下滑",
    "href": "http://stock.jrj.com.cn/2022/08/29080136945139.shtml",
    "datetime": "2022-08-29 08:01:30",
    "code": "688185"
  },
  {
    "title": "A股头条：中国新能源汽车产业已进入全面市场化拓展期；东部战区回应美舰过航台湾海峡；康希诺业绩下滑近99%",
    "href": "http://stock.jrj.com.cn/2022/08/29000336944737.shtml",
    "datetime": "2022-08-29 00:03:09",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟使用最高不超22亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/08/28201936944683.shtml",
    "datetime": "2022-08-28 20:19:29",
    "code": "688185"
  },
  {
    "title": "康希诺：上半年净利同比下降98%",
    "href": "http://stock.jrj.com.cn/2022/08/28160736944163.shtml",
    "datetime": "2022-08-28 16:07:09",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)上半年净利1223.8万元，同比减少98.69%",
    "href": "http://stock.jrj.com.cn/2022/08/28160036944178.shtml",
    "datetime": "2022-08-28 16:00:15",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：2021年年度A股权益分派10派8元 股权登记日8月22日",
    "href": "http://stock.jrj.com.cn/2022/08/16164936904629.shtml",
    "datetime": "2022-08-16 16:49:31",
    "code": "688185"
  },
  {
    "title": "康希诺生物(06185.HK)拟8月26日举行董事会会议审批中期业绩",
    "href": "http://stock.jrj.com.cn/2022/08/12172836895592.shtml",
    "datetime": "2022-08-12 17:28:42",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持59.89万股",
    "href": "http://stock.jrj.com.cn/2022/08/12064136892668.shtml",
    "datetime": "2022-08-12 06:41:45",
    "code": "688185"
  },
  {
    "title": "康希诺生物(06185.HK)遭The Capital Group减持7.38万股",
    "href": "http://stock.jrj.com.cn/2022/08/10063936884886.shtml",
    "datetime": "2022-08-10 06:39:06",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物涨5%上海mRNA产业化基地首期规划产能1亿剂",
    "href": "http://stock.jrj.com.cn/2022/08/05100336872795.shtml",
    "datetime": "2022-08-05 10:03:37",
    "code": "688185"
  },
  {
    "title": "康希诺生物(06185.HK)：截至7月31日累计回购50万股A股",
    "href": "http://stock.jrj.com.cn/2022/08/02173536863340.shtml",
    "datetime": "2022-08-02 17:35:45",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)截至7月底已累计回购50万股A股",
    "href": "http://stock.jrj.com.cn/2022/08/02161636862937.shtml",
    "datetime": "2022-08-02 16:16:39",
    "code": "688185"
  },
  {
    "title": "康希诺：吸入用重组新冠疫苗II期临床现场工作已完成",
    "href": "http://stock.jrj.com.cn/2022/07/14150236811021.shtml",
    "datetime": "2022-07-14 15:02:04",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭The Capital Group减持61.12万股",
    "href": "http://stock.jrj.com.cn/2022/07/07065836789632.shtml",
    "datetime": "2022-07-07 06:58:38",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭The Capital Group减持48.26万股",
    "href": "http://stock.jrj.com.cn/2022/07/05070736782096.shtml",
    "datetime": "2022-07-05 07:07:11",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)截至6月底已累计回购50万股A股",
    "href": "http://stock.jrj.com.cn/2022/07/04164436780191.shtml",
    "datetime": "2022-07-04 16:44:58",
    "code": "688185"
  },
  {
    "title": "康希诺：四价流脑结合疫苗正式在国内上市销售",
    "href": "http://stock.jrj.com.cn/2022/06/30160436771493.shtml",
    "datetime": "2022-06-30 16:04:16",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭摩根大通减持71.9万股",
    "href": "http://stock.jrj.com.cn/2022/06/09064136714406.shtml",
    "datetime": "2022-06-09 06:41:04",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持110.35万股",
    "href": "http://stock.jrj.com.cn/2022/06/07075136707692.shtml",
    "datetime": "2022-06-07 07:51:19",
    "code": "688185"
  },
  {
    "title": "康希诺正式打响销售战：一手终止与“宇宙第一药厂”的合作 一手开高薪招兵买马",
    "href": "http://stock.jrj.com.cn/2022/06/06200636706894.shtml",
    "datetime": "2022-06-06 20:06:15",
    "code": "688185"
  },
  {
    "title": "康希诺与辉瑞终止十年疫苗之约，中外合作模式为何遇阻？",
    "href": "http://stock.jrj.com.cn/2022/06/06194336706784.shtml",
    "datetime": "2022-06-06 19:43:46",
    "code": "688185"
  },
  {
    "title": "10年推广协义突然终止，400亿疫苗白马股与辉瑞“分手”",
    "href": "http://stock.jrj.com.cn/2022/06/06140436705263.shtml",
    "datetime": "2022-06-06 14:04:05",
    "code": "688185"
  },
  {
    "title": "十年合约告吹，康希诺与辉瑞终止关于MCV4疫苗产品的推广合作",
    "href": "http://stock.jrj.com.cn/2022/06/06095636704562.shtml",
    "datetime": "2022-06-06 09:56:04",
    "code": "688185"
  },
  {
    "title": "康希诺生物终止与辉瑞有关MCV4的推广合作",
    "href": "http://stock.jrj.com.cn/2022/06/06091236704387.shtml",
    "datetime": "2022-06-06 09:12:39",
    "code": "688185"
  },
  {
    "title": "A股头条：康希诺终止与辉瑞合作推广四价流脑结合疫苗；小长假海外市场表现各异；本周资本市场大事有这些",
    "href": "http://stock.jrj.com.cn/2022/06/06071136704033.shtml",
    "datetime": "2022-06-06 07:11:58",
    "code": "688185"
  },
  {
    "title": "新冠疫苗龙头终止与辉瑞MCV4疫苗产品推广合作，损及营收前景？",
    "href": "http://stock.jrj.com.cn/2022/06/06065236704002.shtml",
    "datetime": "2022-06-06 06:52:31",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获The Capital Group增持51.08万股",
    "href": "http://stock.jrj.com.cn/2022/06/06062036703981.shtml",
    "datetime": "2022-06-06 06:20:18",
    "code": "688185"
  },
  {
    "title": "十年期协议仅半年就终止，康希诺与辉瑞合作“告吹”！公司称：不会对财务及经营构成重大不利影响",
    "href": "http://stock.jrj.com.cn/2022/06/05213036703869.shtml",
    "datetime": "2022-06-05 21:30:56",
    "code": "688185"
  },
  {
    "title": "康希诺：终止与辉瑞推广合作MCV4疫苗产品曼海欣��",
    "href": "http://stock.jrj.com.cn/2022/06/05201736703823.shtml",
    "datetime": "2022-06-05 20:17:02",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：与辉瑞签署推广服务协议之终止协议",
    "href": "http://stock.jrj.com.cn/2022/06/05163936703582.shtml",
    "datetime": "2022-06-05 16:39:28",
    "code": "688185"
  },
  {
    "title": "康希诺生物(06185.HK)：截至5月底累计回购50万股A股",
    "href": "http://stock.jrj.com.cn/2022/06/02181336701265.shtml",
    "datetime": "2022-06-02 18:13:16",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：截至5月底已累计回购50万股",
    "href": "http://stock.jrj.com.cn/2022/06/02170236700823.shtml",
    "datetime": "2022-06-02 17:02:47",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B盘中涨超10%，是港交所第五家摘“B”生物科技股",
    "href": "http://stock.jrj.com.cn/2022/05/27143836684343.shtml",
    "datetime": "2022-05-27 14:38:03",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物-B涨6% 成港交所第五家去“B”生科股 获增持",
    "href": "http://stock.jrj.com.cn/2022/05/27135836684222.shtml",
    "datetime": "2022-05-27 13:58:13",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获The Capital Group增持115.68万股",
    "href": "http://stock.jrj.com.cn/2022/05/27064736682991.shtml",
    "datetime": "2022-05-27 06:47:31",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：5月31日起股份简称将不再加上标记“B”",
    "href": "http://stock.jrj.com.cn/2022/05/26071136679528.shtml",
    "datetime": "2022-05-26 07:11:18",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获The Capital Group增持117.3万股",
    "href": "http://stock.jrj.com.cn/2022/05/26065936679493.shtml",
    "datetime": "2022-05-26 06:59:25",
    "code": "688185"
  },
  {
    "title": "吸入式新冠疫苗拿到“全球通行证”，康希诺的“新故事”怎么讲？",
    "href": "http://stock.jrj.com.cn/2022/05/24193936675180.shtml",
    "datetime": "2022-05-24 19:39:40",
    "code": "688185"
  },
  {
    "title": "港股异动 |康希诺生物-B跌7% 盘前共有940万股以折让9.6%大手上板",
    "href": "http://stock.jrj.com.cn/2022/05/23131236669887.shtml",
    "datetime": "2022-05-23 13:12:37",
    "code": "688185"
  },
  {
    "title": "康希诺AH股齐跌",
    "href": "http://stock.jrj.com.cn/2022/05/23130236669864.shtml",
    "datetime": "2022-05-23 13:02:14",
    "code": "688185"
  },
  {
    "title": "康希诺拿到“全球通行证”，旗下新冠疫苗克威莎被列入WHO紧急使用清单",
    "href": "http://stock.jrj.com.cn/2022/05/20201236667048.shtml",
    "datetime": "2022-05-20 20:12:20",
    "code": "688185"
  },
  {
    "title": "康希诺新冠疫苗获世卫组织认可，为何券商仍对该行业给出谨慎推荐评级？",
    "href": "http://stock.jrj.com.cn/2022/05/20163036665856.shtml",
    "datetime": "2022-05-20 16:30:15",
    "code": "688185"
  },
  {
    "title": "A股异动 | 生物疫苗股走强 康希诺(688185.SH)涨超15%",
    "href": "http://stock.jrj.com.cn/2022/05/20094436664561.shtml",
    "datetime": "2022-05-20 09:44:06",
    "code": "688185"
  },
  {
    "title": "康希诺：重组新型冠状病毒疫苗被纳入世卫组织紧急使用清单",
    "href": "http://stock.jrj.com.cn/2022/05/20094036664576.shtml",
    "datetime": "2022-05-20 09:40:17",
    "code": "688185"
  },
  {
    "title": "新冠疫苗克威莎列入“紧急使用清单” 康希诺开盘接近涨停",
    "href": "http://stock.jrj.com.cn/2022/05/20092936664445.shtml",
    "datetime": "2022-05-20 09:29:20",
    "code": "688185"
  },
  {
    "title": "开盘：A股三大指数集体高开沪指涨0.33%，康希诺逼近涨停",
    "href": "http://stock.jrj.com.cn/2022/05/20092736664443.shtml",
    "datetime": "2022-05-20 09:27:58",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：克威莎纳入世界卫生组织紧急使用清单",
    "href": "http://stock.jrj.com.cn/2022/05/20072136664202.shtml",
    "datetime": "2022-05-20 07:21:01",
    "code": "688185"
  },
  {
    "title": "A股头条：美股延续跌势中概股逆势上扬；王良任招商银行第四任行长；康希诺新冠疫苗获批全球紧急使用",
    "href": "http://stock.jrj.com.cn/2022/05/20061236664121.shtml",
    "datetime": "2022-05-20 06:12:15",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：重组新型冠状病毒疫苗(5型腺病毒载体)被纳入WHO紧急使用清单",
    "href": "http://stock.jrj.com.cn/2022/05/19222336663848.shtml",
    "datetime": "2022-05-19 22:23:08",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：截至4月底已累计回购35万股",
    "href": "http://stock.jrj.com.cn/2022/05/06160236580688.shtml",
    "datetime": "2022-05-06 16:02:36",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B2022年首季归母净利1.21亿元，同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2022/04/29171736505166.shtml",
    "datetime": "2022-04-29 17:17:05",
    "code": "688185"
  },
  {
    "title": "扭亏为盈 康希诺2022年一季度净利润1.21亿元",
    "href": "http://stock.jrj.com.cn/2022/04/29092436500810.shtml",
    "datetime": "2022-04-29 09:24:23",
    "code": "688185"
  },
  {
    "title": "康希诺：一季度净利1.2亿元",
    "href": "http://stock.jrj.com.cn/2022/04/28183636494182.shtml",
    "datetime": "2022-04-28 18:36:36",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)获核准发行不超60亿港元的H股可转债",
    "href": "http://stock.jrj.com.cn/2022/04/19170436399614.shtml",
    "datetime": "2022-04-19 17:04:16",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)4月14日耗资488万元回购2.5万股A股",
    "href": "http://stock.jrj.com.cn/2022/04/14165836335437.shtml",
    "datetime": "2022-04-14 16:58:48",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)4月28日举行董事会会议审批一季度业绩",
    "href": "http://stock.jrj.com.cn/2022/04/12175136316067.shtml",
    "datetime": "2022-04-12 17:51:36",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭摩根大通减持21.82万股",
    "href": "http://stock.jrj.com.cn/2022/04/07070936266239.shtml",
    "datetime": "2022-04-07 07:09:27",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：截至3月底已累计回购32.5万股",
    "href": "http://stock.jrj.com.cn/2022/04/06161236262841.shtml",
    "datetime": "2022-04-06 16:12:13",
    "code": "688185"
  },
  {
    "title": "康希诺新冠mRNA疫苗获批临床 后续推进值得期待",
    "href": "http://stock.jrj.com.cn/2022/04/06082036260521.shtml",
    "datetime": "2022-04-06 08:20:35",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持21.34万股",
    "href": "http://stock.jrj.com.cn/2022/04/06073436260365.shtml",
    "datetime": "2022-04-06 07:34:49",
    "code": "688185"
  },
  {
    "title": "康希诺：新型冠状病毒mRNA疫苗获得药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/04/05154436257732.shtml",
    "datetime": "2022-04-05 15:44:46",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：新型冠状病毒mRNA疫苗获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/04/05153636257714.shtml",
    "datetime": "2022-04-05 15:36:48",
    "code": "688185"
  },
  {
    "title": "康希诺生物：新冠病毒mRNA疫苗获国家药监局药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/04/04082136252996.shtml",
    "datetime": "2022-04-04 08:21:56",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：新冠病毒mRNA疫苗获得国家药监局药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2022/04/04080436252935.shtml",
    "datetime": "2022-04-04 08:04:02",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭The Capital Group减持16.8万股",
    "href": "http://stock.jrj.com.cn/2022/04/04072436252892.shtml",
    "datetime": "2022-04-04 07:24:23",
    "code": "688185"
  },
  {
    "title": "方正证券点评康希诺：新冠疫苗带动业绩爆发式增长，在研产品渐入收获期",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/01084936244919.shtml",
    "datetime": "2022-04-01 08:49:07",
    "code": "688185"
  },
  {
    "title": "康希诺业绩扭亏 但一款药品难撑起业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/30083136265047.shtml",
    "datetime": "2022-03-30 08:31:00",
    "code": "688185"
  },
  {
    "title": "康希诺业绩扭亏 但一款药品难撑起业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/30083136251465.shtml",
    "datetime": "2022-03-30 08:31:00",
    "code": "688185"
  },
  {
    "title": "康希诺业绩扭亏 但一款药品难撑起业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/30083136183114.shtml",
    "datetime": "2022-03-30 08:31:00",
    "code": "688185"
  },
  {
    "title": "康希诺2021年净利19.14亿同比扭亏为盈 董事长宇学峰薪酬444.4万",
    "href": "http://stock.jrj.com.cn/2022/03/28125035841603.shtml",
    "datetime": "2022-03-28 12:50:16",
    "code": "688185"
  },
  {
    "title": "科创板首个摘“U”生物科技公司，康希诺新冠疫苗已多国上市，2021年实现扭亏为盈",
    "href": "http://stock.jrj.com.cn/2022/03/28102035812792.shtml",
    "datetime": "2022-03-28 10:20:05",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟使用不超40亿元暂时闲置自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/03/27174435596696.shtml",
    "datetime": "2022-03-27 17:44:04",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：首次实现年度盈利 3月29日起摘“U”",
    "href": "http://stock.jrj.com.cn/2022/03/27164335584319.shtml",
    "datetime": "2022-03-27 16:43:15",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)2021年度业绩扭亏为盈至19.14亿元 拟10派8元",
    "href": "http://stock.jrj.com.cn/2022/03/27155535572636.shtml",
    "datetime": "2022-03-27 15:55:23",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持16.5万股",
    "href": "http://stock.jrj.com.cn/2022/03/14072434821573.shtml",
    "datetime": "2022-03-14 07:24:50",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)3月25日举行董事会会议审批年度业绩",
    "href": "http://stock.jrj.com.cn/2022/03/11171534814448.shtml",
    "datetime": "2022-03-11 17:15:18",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物-B涨7% 获The Capital Group增持12.5万股",
    "href": "http://stock.jrj.com.cn/2022/03/10145334808499.shtml",
    "datetime": "2022-03-10 14:53:05",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获The Capital Group增持12.5万股",
    "href": "http://stock.jrj.com.cn/2022/03/10072234769054.shtml",
    "datetime": "2022-03-10 07:22:17",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物-B跌7% 两股东累计减持616.3万股A股",
    "href": "http://stock.jrj.com.cn/2022/03/08143734540905.shtml",
    "datetime": "2022-03-08 14:37:09",
    "code": "688185"
  },
  {
    "title": "康希诺2名股东合计减持616.34万股 套现合计17.2亿 2021年公司净利19.14亿",
    "href": "http://stock.jrj.com.cn/2022/03/07185434538474.shtml",
    "datetime": "2022-03-07 18:54:47",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：上海礼安和苏州礼泰合计减持616.34万股",
    "href": "http://stock.jrj.com.cn/2022/03/07171134538070.shtml",
    "datetime": "2022-03-07 17:11:24",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：减持期届满 上海礼安、苏州礼泰合计减持2.49%股份",
    "href": "http://stock.jrj.com.cn/2022/03/07160934537727.shtml",
    "datetime": "2022-03-07 16:09:42",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：截至2月底累计回购32.5万股A股",
    "href": "http://stock.jrj.com.cn/2022/03/01160434508135.shtml",
    "datetime": "2022-03-01 16:04:28",
    "code": "688185"
  },
  {
    "title": "港股已率先“闻鸡起舞”，康希诺生物盘中一度大涨！康希诺：重组新冠疫苗获批用于序贯加强免疫接种",
    "href": "http://stock.jrj.com.cn/2022/02/21152734422349.shtml",
    "datetime": "2022-02-21 15:27:47",
    "code": "688185"
  },
  {
    "title": "开盘：沪指微跌创业板指涨0.13%，东数西算概念领涨，康希诺高开6.75％",
    "href": "http://stock.jrj.com.cn/2022/02/21092734417961.shtml",
    "datetime": "2022-02-21 09:27:44",
    "code": "688185"
  },
  {
    "title": "康希诺：重组新型冠状病毒疫苗(5型腺病毒载体)获批用于序贯加强免疫接种",
    "href": "http://stock.jrj.com.cn/2022/02/20160734415203.shtml",
    "datetime": "2022-02-20 16:07:02",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：重组新冠病毒疫苗(5型腺病毒载体)获批用于序贯加强免疫接种",
    "href": "http://stock.jrj.com.cn/2022/02/20155434415166.shtml",
    "datetime": "2022-02-20 15:54:53",
    "code": "688185"
  },
  {
    "title": "智飞生物和康希诺AH股齐步拉升 入选中国新冠疫苗加强针“混打”方案",
    "href": "http://stock.jrj.com.cn/2022/02/18145534389780.shtml",
    "datetime": "2022-02-18 14:55:23",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭The Capital Group减持13.1万股",
    "href": "http://stock.jrj.com.cn/2022/02/16065834362038.shtml",
    "datetime": "2022-02-16 06:58:00",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：礼来亚洲基金的投资主体已合计减持794.4792万股 持股降至4.99%",
    "href": "http://stock.jrj.com.cn/2022/02/14161634344723.shtml",
    "datetime": "2022-02-14 16:16:15",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物-B涨7% 耗资2681.77万元回购10.2万股A股",
    "href": "http://stock.jrj.com.cn/2022/02/10102334317285.shtml",
    "datetime": "2022-02-10 10:23:34",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：2月7日首次回购15万股",
    "href": "http://stock.jrj.com.cn/2022/02/07164134301921.shtml",
    "datetime": "2022-02-07 16:41:40",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获The Capital Group增持7.52万股",
    "href": "http://stock.jrj.com.cn/2022/02/07063534297617.shtml",
    "datetime": "2022-02-07 06:35:17",
    "code": "688185"
  },
  {
    "title": "康希诺生物预计扭亏 研发投入增长2.7倍",
    "href": "http://stock.jrj.com.cn/2022/01/29095934255041.shtml",
    "datetime": "2022-01-29 09:59:00",
    "code": "688185"
  },
  {
    "title": "康希诺将花不超3亿元回购公司股份 用于股权激励",
    "href": "http://stock.jrj.com.cn/2022/01/28211034248731.shtml",
    "datetime": "2022-01-28 21:10:59",
    "code": "688185"
  },
  {
    "title": "康希诺：预计2021年净利18.5亿元-20亿元 将实现扭亏为盈",
    "href": "http://stock.jrj.com.cn/2022/01/28174634243519.shtml",
    "datetime": "2022-01-28 17:46:23",
    "code": "688185"
  },
  {
    "title": "康希诺：预计2021年净利18.5亿元-20亿元 将实现扭亏为盈",
    "href": "http://stock.jrj.com.cn/2022/01/28174634243518.shtml",
    "datetime": "2022-01-28 17:46:13",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：2021年度预盈18.5亿元-20亿元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2022/01/28174434243506.shtml",
    "datetime": "2022-01-28 17:44:55",
    "code": "688185"
  },
  {
    "title": "A股异动 | 康希诺盘中涨近10% 上药康希诺单针新冠疫苗量产上市",
    "href": "http://stock.jrj.com.cn/2022/01/27140734230011.shtml",
    "datetime": "2022-01-27 14:07:13",
    "code": "688185"
  },
  {
    "title": "A股异动 | 康希诺盘中涨6% 拟斥资1.5亿-3亿元回购A股股份",
    "href": "http://stock.jrj.com.cn/2022/01/24100634200158.shtml",
    "datetime": "2022-01-24 10:06:59",
    "code": "688185"
  },
  {
    "title": "康希诺：拟以1.5亿元-3亿元回购股份",
    "href": "http://stock.jrj.com.cn/2022/01/23160634194229.shtml",
    "datetime": "2022-01-23 16:06:01",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟以1.5亿元-3亿元回购公司A股",
    "href": "http://stock.jrj.com.cn/2022/01/23155734194202.shtml",
    "datetime": "2022-01-23 15:57:06",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：4名股东1月11日合计减持H股315万股",
    "href": "http://stock.jrj.com.cn/2022/01/12162634150089.shtml",
    "datetime": "2022-01-12 16:26:17",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：持股5%以上股东减持数量过半",
    "href": "http://stock.jrj.com.cn/2022/01/11171934146563.shtml",
    "datetime": "2022-01-11 17:19:40",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：上海礼安和苏州礼泰已合计减持1.85%的股份",
    "href": "http://stock.jrj.com.cn/2022/01/11161434146179.shtml",
    "datetime": "2022-01-11 16:14:34",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭美国资本集团减持28.06万股",
    "href": "http://stock.jrj.com.cn/2022/01/10065034139140.shtml",
    "datetime": "2022-01-10 06:50:34",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺(6185.HK)涨超7% 马来西亚批准其新冠疫苗作为加强针",
    "href": "http://stock.jrj.com.cn/2022/01/07101734132489.shtml",
    "datetime": "2022-01-07 10:17:47",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物跌9% 隔晚美股疫苗股大跌",
    "href": "http://stock.jrj.com.cn/2022/01/04113434120743.shtml",
    "datetime": "2022-01-04 11:34:46",
    "code": "688185"
  },
  {
    "title": "康希诺膜炎球菌多糖结合疫苗获《药品注册证书》：自称填补在该领域缺乏高端疫苗空白",
    "href": "http://stock.jrj.com.cn/2021/12/29133234080655.shtml",
    "datetime": "2021-12-29 13:32:46",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)短线拉升 四价脑膜炎结合疫苗MCV4获批上市",
    "href": "http://stock.jrj.com.cn/2021/12/29110934080273.shtml",
    "datetime": "2021-12-29 11:09:13",
    "code": "688185"
  },
  {
    "title": "康希诺生物：重组新型冠状病毒疫苗保护率达到WHO相关技术标准",
    "href": "http://stock.jrj.com.cn/2021/12/24110034056746.shtml",
    "datetime": "2021-12-24 11:00:28",
    "code": "688185"
  },
  {
    "title": "康希诺AH股齐拉升 新冠疫苗Ad5-nCoV保护率达世卫组织相关技术标准",
    "href": "http://stock.jrj.com.cn/2021/12/24095034056417.shtml",
    "datetime": "2021-12-24 09:50:48",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：单剂Ad5-nCoV在18岁及以上健康成年人中安全有效",
    "href": "http://stock.jrj.com.cn/2021/12/24083234056077.shtml",
    "datetime": "2021-12-24 08:32:54",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获美国资本集团增持54.3万股",
    "href": "http://stock.jrj.com.cn/2021/12/23065234050004.shtml",
    "datetime": "2021-12-23 06:52:41",
    "code": "688185"
  },
  {
    "title": "康希诺(6185.HK)涨幅扩大至15% 宣布与Aerogen开发全球首款吸入式新冠疫苗",
    "href": "http://stock.jrj.com.cn/2021/12/15135634019215.shtml",
    "datetime": "2021-12-15 13:56:54",
    "code": "688185"
  },
  {
    "title": "A股异动 | 康希诺涨5% 正在开展针对奥密克戎变异株的新冠疫苗开发工作",
    "href": "http://stock.jrj.com.cn/2021/12/15101434018276.shtml",
    "datetime": "2021-12-15 10:14:11",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：股东上海礼安和苏州礼泰累计减持1.46%股份 减持计划未实施完毕",
    "href": "http://stock.jrj.com.cn/2021/12/05160433965237.shtml",
    "datetime": "2021-12-05 16:04:54",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获美国资本集团增持18.42万股",
    "href": "http://stock.jrj.com.cn/2021/12/03071433958481.shtml",
    "datetime": "2021-12-03 07:14:36",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持29.98万股",
    "href": "http://stock.jrj.com.cn/2021/12/02082333953758.shtml",
    "datetime": "2021-12-02 08:23:39",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：上海礼安及其一致行动人苏州礼泰累计减持1.26%股份 持股比例减至6.94%",
    "href": "http://stock.jrj.com.cn/2021/11/30161233944347.shtml",
    "datetime": "2021-11-30 16:12:38",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)拟购买7亿元结构性存款",
    "href": "http://stock.jrj.com.cn/2021/11/19173233880725.shtml",
    "datetime": "2021-11-19 17:32:09",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：重组新冠疫苗(5型腺病毒载体)在阿根廷获推荐作为加强接种和额外接种的异源疫苗",
    "href": "http://stock.jrj.com.cn/2021/11/15074233852432.shtml",
    "datetime": "2021-11-15 07:42:54",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭美国资本集团减持55.94万股",
    "href": "http://stock.jrj.com.cn/2021/11/15065533852145.shtml",
    "datetime": "2021-11-15 06:55:30",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)购买7亿元结构性存款",
    "href": "http://stock.jrj.com.cn/2021/11/11163933836575.shtml",
    "datetime": "2021-11-11 16:39:45",
    "code": "688185"
  },
  {
    "title": "前三季度营收大增543倍，突遭投资者质疑，疫苗龙头康希诺回应来了",
    "href": "http://stock.jrj.com.cn/2021/11/03214933809865.shtml",
    "datetime": "2021-11-03 21:49:25",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获美国资本集团增持56.02万股",
    "href": "http://stock.jrj.com.cn/2021/11/01071933795057.shtml",
    "datetime": "2021-11-01 07:19:41",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B前三财季净利13.34亿元，同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/10/29133333776604.shtml",
    "datetime": "2021-10-29 13:33:31",
    "code": "688185"
  },
  {
    "title": "康希诺AH均大跌 克威莎收入环比下滑",
    "href": "http://stock.jrj.com.cn/2021/10/29102733775729.shtml",
    "datetime": "2021-10-29 10:27:22",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)购买结构性存款",
    "href": "http://stock.jrj.com.cn/2021/10/28173933770122.shtml",
    "datetime": "2021-10-28 17:39:26",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)第三季度净利润3.97亿元",
    "href": "http://stock.jrj.com.cn/2021/10/28165733769614.shtml",
    "datetime": "2021-10-28 16:57:15",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物-B(6185.HK)涨逾6% 披露“克威莎”吸入剂型新冠疫苗最新临床研究进展",
    "href": "http://stock.jrj.com.cn/2021/10/18094533709221.shtml",
    "datetime": "2021-10-18 09:45:22",
    "code": "688185"
  },
  {
    "title": "康希诺跌9.66% 中信证券西南证券上月初喊买",
    "href": "http://stock.jrj.com.cn/2021/10/08173533658650.shtml",
    "datetime": "2021-10-08 17:35:00",
    "code": "688185"
  },
  {
    "title": "新冠口服药迎突破，A股生物疫苗板块走弱，康希诺等纷纷下跌",
    "href": "http://stock.jrj.com.cn/2021/10/08094233655936.shtml",
    "datetime": "2021-10-08 09:42:59",
    "code": "688185"
  },
  {
    "title": "巴西将引进中国康希诺新冠疫苗",
    "href": "http://stock.jrj.com.cn/2021/10/02082833553443.shtml",
    "datetime": "2021-10-02 08:28:03",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟使用11.9亿元超募资金永久补充流动资金",
    "href": "http://stock.jrj.com.cn/2021/09/10211833417111.shtml",
    "datetime": "2021-09-10 21:18:16",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：向激励对象授予首次授予87.53万股、预留授予4.97万股限制性股票",
    "href": "http://stock.jrj.com.cn/2021/09/10192333416581.shtml",
    "datetime": "2021-09-10 19:23:17",
    "code": "688185"
  },
  {
    "title": "康希诺生物：用Ad5腺病毒载体新冠疫苗加强后抗体水平升高78倍",
    "href": "http://stock.jrj.com.cn/2021/09/07151933398287.shtml",
    "datetime": "2021-09-07 15:19:06",
    "code": "688185"
  },
  {
    "title": "康希诺2021年半年度净利9.37亿元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/08/30115633350990.shtml",
    "datetime": "2021-08-30 11:56:03",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)半年度业绩扭亏为盈至9.37亿元",
    "href": "http://stock.jrj.com.cn/2021/08/29192533341239.shtml",
    "datetime": "2021-08-29 19:25:28",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟推110.025万股2021年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2021/08/20180133288224.shtml",
    "datetime": "2021-08-20 18:01:26",
    "code": "688185"
  },
  {
    "title": "康希诺股价走低两个月不到跌去45% 两大股东解禁首日计划清仓或套现37亿",
    "href": "http://stock.jrj.com.cn/2021/08/16155333260589.shtml",
    "datetime": "2021-08-16 15:53:43",
    "code": "688185"
  },
  {
    "title": "迎来解禁股东就想抛售清仓减持，千亿疫苗康希诺如何应对股价暴跌？",
    "href": "http://stock.jrj.com.cn/2021/08/16103733258989.shtml",
    "datetime": "2021-08-16 10:37:31",
    "code": "688185"
  },
  {
    "title": "康希诺2名股东拟合计减持不超770.95万股公司股份 一季度公司亏损1411.41万",
    "href": "http://stock.jrj.com.cn/2021/08/13203133250524.shtml",
    "datetime": "2021-08-13 20:31:48",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：上海礼安和苏州礼泰拟减持不超3.12%的股份",
    "href": "http://stock.jrj.com.cn/2021/08/13165833249266.shtml",
    "datetime": "2021-08-13 16:58:39",
    "code": "688185"
  },
  {
    "title": "康希诺：股东拟减持公司不超3.12%股份",
    "href": "http://stock.jrj.com.cn/2021/08/13165133249219.shtml",
    "datetime": "2021-08-13 16:51:32",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B跌8.11%，医疗板块迎调整期，恒生医疗ETF(513060)半日成交近5000万",
    "href": "http://stock.jrj.com.cn/2021/08/12111933241892.shtml",
    "datetime": "2021-08-12 11:19:20",
    "code": "688185"
  },
  {
    "title": "港股医疗板块震荡调整，康希诺生物跌破13%，恒生医疗ETF（513060)20日吸金1.3亿",
    "href": "http://stock.jrj.com.cn/2021/08/11142433237151.shtml",
    "datetime": "2021-08-11 14:24:14",
    "code": "688185"
  },
  {
    "title": "三大股东浮盈超百亿！“消费电子茅”下周解禁超300亿元，还有这些股解禁压力大（附名单）",
    "href": "http://stock.jrj.com.cn/2021/08/08143733218102.shtml",
    "datetime": "2021-08-08 14:37:00",
    "code": "688185"
  },
  {
    "title": "康希诺生物等多家公司正开展对变异株的新冠疫苗开发工作",
    "href": "http://stock.jrj.com.cn/2021/08/06101233211464.shtml",
    "datetime": "2021-08-06 10:12:21",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：4279.3786万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2021/08/04163933201621.shtml",
    "datetime": "2021-08-04 16:39:08",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获美国资本集团增持28.1万股",
    "href": "http://stock.jrj.com.cn/2021/08/03064733191807.shtml",
    "datetime": "2021-08-03 06:47:25",
    "code": "688185"
  },
  {
    "title": "康希诺AH股齐步走强 吸入用新冠疫苗临床试验结果获权威认可",
    "href": "http://stock.jrj.com.cn/2021/07/28133733163511.shtml",
    "datetime": "2021-07-28 13:37:38",
    "code": "688185"
  },
  {
    "title": "康希诺生物扭亏为盈，港股生物板块逆势上涨，恒生医疗ETF（513060）涨超1%",
    "href": "http://stock.jrj.com.cn/2021/07/19120833118200.shtml",
    "datetime": "2021-07-19 12:08:37",
    "code": "688185"
  },
  {
    "title": "康希诺2021年上半年预计净利9亿-10.5亿同比扭亏为盈 闲置资金现金管理收益增加",
    "href": "http://stock.jrj.com.cn/2021/07/16194233108937.shtml",
    "datetime": "2021-07-16 19:42:13",
    "code": "688185"
  },
  {
    "title": "【公告抢先看】晚间公告：格力电器已耗资36.77亿元回购1.17%股份、康希诺上半年预盈9亿元-10.5亿元",
    "href": "http://stock.jrj.com.cn/2021/07/16180933108492.shtml",
    "datetime": "2021-07-16 18:09:47",
    "code": "688185"
  },
  {
    "title": "康希诺2021年上半年盈利超9亿元：近5年来首次盈利",
    "href": "http://stock.jrj.com.cn/2021/07/16174833108375.shtml",
    "datetime": "2021-07-16 17:48:36",
    "code": "688185"
  },
  {
    "title": "康希诺：上半年预盈9亿元-10.5亿元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2021/07/16173033108214.shtml",
    "datetime": "2021-07-16 17:30:59",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：上药康希诺拟向上海医药方面借调部分人员为其提供技术咨询、综合管理等服务",
    "href": "http://stock.jrj.com.cn/2021/07/16172433108190.shtml",
    "datetime": "2021-07-16 17:24:07",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)半年度净利预计为9-10.5亿元 实现扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/07/16172233108156.shtml",
    "datetime": "2021-07-16 17:22:23",
    "code": "688185"
  },
  {
    "title": "外资巨头出手！大举减持1600亿疫苗大白马 一把套现29亿！发生了什么？",
    "href": "http://stock.jrj.com.cn/2021/06/26070532999726.shtml",
    "datetime": "2021-06-26 07:05:35",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭非执行董事梁頴宇减持9.72万股",
    "href": "http://stock.jrj.com.cn/2021/06/25085632994139.shtml",
    "datetime": "2021-06-25 08:56:42",
    "code": "688185"
  },
  {
    "title": "康希诺生物脑膜炎疫苗获得药监局授予新药申请批准",
    "href": "http://stock.jrj.com.cn/2021/06/23172032983746.shtml",
    "datetime": "2021-06-23 17:20:16",
    "code": "688185"
  },
  {
    "title": "脑膜炎疫苗获批上市 康希诺H股大涨10% A股创上市新高",
    "href": "http://stock.jrj.com.cn/2021/06/23095732981039.shtml",
    "datetime": "2021-06-23 09:57:02",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(6185.HK)涨4.48% 全国新冠疫苗接种超10亿剂次",
    "href": "http://stock.jrj.com.cn/2021/06/21103632968019.shtml",
    "datetime": "2021-06-21 10:36:45",
    "code": "688185"
  },
  {
    "title": "旗下1针疫苗在广东开打 康希诺A股涨超8%创新高 年内累涨近80%",
    "href": "http://stock.jrj.com.cn/2021/06/11113132910211.shtml",
    "datetime": "2021-06-11 11:31:52",
    "code": "688185"
  },
  {
    "title": "康希诺AH股均涨超10% 雾化吸入式新冠疫苗正申请紧急使用",
    "href": "http://stock.jrj.com.cn/2021/06/07134732886525.shtml",
    "datetime": "2021-06-07 13:47:25",
    "code": "688185"
  },
  {
    "title": "长阳科技等5只个股调出科创50指数名单 凯赛生物、康希诺、圣湘生物等5只调入",
    "href": "http://stock.jrj.com.cn/2021/06/07093232885624.shtml",
    "datetime": "2021-06-07 09:32:24",
    "code": "688185"
  },
  {
    "title": "港股异动 | 康希诺生物-B(6185.HK)逆势涨4.6% 旗下鼻喷雾式/吸入型新冠疫苗正在申请紧急使用",
    "href": "http://stock.jrj.com.cn/2021/06/04094232872783.shtml",
    "datetime": "2021-06-04 09:42:14",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：Zhongqi SHAO获委任为监事",
    "href": "http://stock.jrj.com.cn/2021/05/28225032837312.shtml",
    "datetime": "2021-05-28 22:50:42",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)一度拉升涨超15% 腺病毒载体重组新冠疫苗开始供应",
    "href": "http://stock.jrj.com.cn/2021/05/19144032781585.shtml",
    "datetime": "2021-05-19 14:40:27",
    "code": "688185"
  },
  {
    "title": "疫苗板块午后拉升 康希诺大涨超10%",
    "href": "http://stock.jrj.com.cn/2021/05/19134532781391.shtml",
    "datetime": "2021-05-19 13:45:49",
    "code": "688185"
  },
  {
    "title": "康希诺生物联合上药三维增资上药康希诺合共11亿元，出资用作生产新冠疫苗",
    "href": "http://stock.jrj.com.cn/2021/05/18101432774407.shtml",
    "datetime": "2021-05-18 10:14:36",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：上药康希诺注册资本将增加至12.05亿元",
    "href": "http://stock.jrj.com.cn/2021/05/17220032771512.shtml",
    "datetime": "2021-05-17 22:00:52",
    "code": "688185"
  },
  {
    "title": "康希诺、智飞生物领涨疫苗股 国内多点零星病例再现",
    "href": "http://stock.jrj.com.cn/2021/05/17101232767935.shtml",
    "datetime": "2021-05-17 10:12:10",
    "code": "688185"
  },
  {
    "title": "港股异动丨利好叠加 康希诺AH股同步拉升超7%",
    "href": "http://stock.jrj.com.cn/2021/05/14110132753982.shtml",
    "datetime": "2021-05-14 11:01:55",
    "code": "688185"
  },
  {
    "title": "疫苗股重挫，复星医药跌停，康希诺、沃森生物跌超14％，港股疫苗概念股同步大跌，海通证券：无需过分担心",
    "href": "http://stock.jrj.com.cn/2021/05/06101532699978.shtml",
    "datetime": "2021-05-06 10:15:41",
    "code": "688185"
  },
  {
    "title": "美国将放弃新冠肺炎疫苗专利，疫苗股全线大跌，康希诺开盘跌逾12%",
    "href": "http://stock.jrj.com.cn/2021/05/06093232699702.shtml",
    "datetime": "2021-05-06 09:32:01",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持27.44万股",
    "href": "http://stock.jrj.com.cn/2021/05/05073632660264.shtml",
    "datetime": "2021-05-05 07:36:45",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭摩根大通减持35.1万股",
    "href": "http://stock.jrj.com.cn/2021/05/04063332617042.shtml",
    "datetime": "2021-05-04 06:33:48",
    "code": "688185"
  },
  {
    "title": "A股异动 | 康希诺(688185.SH)大涨8.63% 一季度亏损收窄至1411.4万元",
    "href": "http://stock.jrj.com.cn/2021/04/30142832486813.shtml",
    "datetime": "2021-04-30 14:28:48",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持35.37万股",
    "href": "http://stock.jrj.com.cn/2021/04/30065932484041.shtml",
    "datetime": "2021-04-30 06:59:48",
    "code": "688185"
  },
  {
    "title": "环球印务：公司与天津康希诺、安徽智飞龙科马等新冠疫苗生产企业已开展合作",
    "href": "http://stock.jrj.com.cn/2021/04/26133232453384.shtml",
    "datetime": "2021-04-26 13:32:21",
    "code": "688185"
  },
  {
    "title": "康希诺AH股齐飙 昨日举行“新冠疫苗三期生产基地产品下线仪式”",
    "href": "http://stock.jrj.com.cn/2021/04/26102832452394.shtml",
    "datetime": "2021-04-26 10:28:48",
    "code": "688185"
  },
  {
    "title": "开发单剂疫苗 康希诺AH股齐拉升",
    "href": "http://stock.jrj.com.cn/2021/04/19102132399970.shtml",
    "datetime": "2021-04-19 10:21:54",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)4月29日举行董事会会议审批一季度业绩",
    "href": "http://stock.jrj.com.cn/2021/04/15165632380210.shtml",
    "datetime": "2021-04-15 16:56:48",
    "code": "688185"
  },
  {
    "title": "康希诺AH均大跌 国外相同技术新冠疫苗相继现血栓副作用",
    "href": "http://stock.jrj.com.cn/2021/04/14101332369775.shtml",
    "datetime": "2021-04-14 10:13:59",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：13价肺炎球菌多糖结合疫苗(CRM197，TT载体)III期临床试验入组",
    "href": "http://stock.jrj.com.cn/2021/04/13185532366408.shtml",
    "datetime": "2021-04-13 18:55:03",
    "code": "688185"
  },
  {
    "title": "康希诺：PCV13i进入Ⅲ期临床试验",
    "href": "http://stock.jrj.com.cn/2021/04/13180632366118.shtml",
    "datetime": "2021-04-13 18:06:30",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：13价肺炎球菌多糖结合疫苗(CRM197，TT载体)进入Ⅲ期临床试验",
    "href": "http://stock.jrj.com.cn/2021/04/13163332365381.shtml",
    "datetime": "2021-04-13 16:33:37",
    "code": "688185"
  },
  {
    "title": "康希诺去年亏损3.97亿 董事长宇学峰：今年第一重点是新冠疫苗生产和供应",
    "href": "http://stock.jrj.com.cn/2021/03/29200132242968.shtml",
    "datetime": "2021-03-29 20:01:03",
    "code": "688185"
  },
  {
    "title": "疫苗产品尚未实现商业化销售 康希诺去年亏损近4亿元",
    "href": "http://stock.jrj.com.cn/2021/03/29102432239243.shtml",
    "datetime": "2021-03-29 10:24:26",
    "code": "688185"
  },
  {
    "title": "康希诺2020年亏损3.97亿亏损增加：董事长宇学锋薪酬665.36万",
    "href": "http://stock.jrj.com.cn/2021/03/28200832231154.shtml",
    "datetime": "2021-03-28 20:08:29",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)：拟使用最高不超30亿元暂时闲置自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/03/28151732229573.shtml",
    "datetime": "2021-03-28 15:17:00",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)2020年亏损达3.97亿元",
    "href": "http://stock.jrj.com.cn/2021/03/28145332229496.shtml",
    "datetime": "2021-03-28 14:53:12",
    "code": "688185"
  },
  {
    "title": "康希诺年度报告：2020年净亏损3.97亿元 亏损扩大",
    "href": "http://stock.jrj.com.cn/2021/03/28142032229425.shtml",
    "datetime": "2021-03-28 14:20:18",
    "code": "688185"
  },
  {
    "title": "康希诺与3个欧盟国家商谈新冠疫苗订单？董事长宇学峰：“有很多”",
    "href": "http://stock.jrj.com.cn/2021/03/27180832227639.shtml",
    "datetime": "2021-03-27 18:08:21",
    "code": "688185"
  },
  {
    "title": "康希诺董事长宇学峰：高需求下，疫苗企业共同面临原材料、耗材供应等产业链挑战",
    "href": "http://stock.jrj.com.cn/2021/03/26122432222033.shtml",
    "datetime": "2021-03-26 12:24:12",
    "code": "688185"
  },
  {
    "title": "康希诺AH齐涨 吸入用重组新冠病毒疫苗获得国家药监局药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/03/23095732199764.shtml",
    "datetime": "2021-03-23 09:57:23",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：吸入用重组新冠病毒疫苗(5型腺病毒载体)获得国家药品监督管理局药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2021/03/23061532197867.shtml",
    "datetime": "2021-03-23 06:15:40",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：重组新冠病毒疫苗(5型腺病毒载体)于匈牙利获得紧急使用授权",
    "href": "http://stock.jrj.com.cn/2021/03/22080432189411.shtml",
    "datetime": "2021-03-22 08:04:07",
    "code": "688185"
  },
  {
    "title": "康希诺跌4.6% 市值755亿元去年亏损4亿元",
    "href": "http://stock.jrj.com.cn/2021/03/19180432165218.shtml",
    "datetime": "2021-03-19 18:04:00",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)3月26日举行董事会会议审批全年业绩",
    "href": "http://stock.jrj.com.cn/2021/03/10164532103951.shtml",
    "datetime": "2021-03-10 16:45:02",
    "code": "688185"
  },
  {
    "title": "康希诺跌5.5% 市值924亿元去年亏损4亿元",
    "href": "http://stock.jrj.com.cn/2021/03/02180232058561.shtml",
    "datetime": "2021-03-02 18:02:00",
    "code": "688185"
  },
  {
    "title": "只需一针！第三个国产新冠疫苗上市在即，或成康希诺扭亏担当",
    "href": "http://stock.jrj.com.cn/2021/03/02072532054692.shtml",
    "datetime": "2021-03-02 07:25:40",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭摩根大通减持34.5万股",
    "href": "http://stock.jrj.com.cn/2021/03/01074932047635.shtml",
    "datetime": "2021-03-01 07:49:50",
    "code": "688185"
  },
  {
    "title": "康希诺新冠疫苗获批上市 如何用4亿亏损撑起千亿市值？",
    "href": "http://stock.jrj.com.cn/2021/02/26152732032889.shtml",
    "datetime": "2021-02-26 15:27:22",
    "code": "688185"
  },
  {
    "title": "加大研发投入等 康希诺去年亏损4.07亿元",
    "href": "http://stock.jrj.com.cn/2021/02/26095532031322.shtml",
    "datetime": "2021-02-26 09:55:09",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获美国资本集团增持4.62万股",
    "href": "http://stock.jrj.com.cn/2021/02/26082732030639.shtml",
    "datetime": "2021-02-26 08:27:25",
    "code": "688185"
  },
  {
    "title": "A股头条：国药中生、康希诺新冠疫苗注册申请获批，这些中小盘股被明星机构盯上了",
    "href": "http://stock.jrj.com.cn/2021/02/26054232029391.shtml",
    "datetime": "2021-02-26 05:42:25",
    "code": "688185"
  },
  {
    "title": "康希诺2020年度亏损4.07亿同比亏损增加 研发费用大幅上升",
    "href": "http://stock.jrj.com.cn/2021/02/25190632027260.shtml",
    "datetime": "2021-02-25 19:06:58",
    "code": "688185"
  },
  {
    "title": "康希诺(688185.SH)业绩快报：2020年营收2489.04万元 同比增长990.06%",
    "href": "http://stock.jrj.com.cn/2021/02/25161832025814.shtml",
    "datetime": "2021-02-25 16:18:06",
    "code": "688185"
  },
  {
    "title": "康希诺业绩快报：2020年亏损4.07亿元",
    "href": "http://stock.jrj.com.cn/2021/02/25161632025803.shtml",
    "datetime": "2021-02-25 16:16:47",
    "code": "688185"
  },
  {
    "title": "【公告抢先看】晚间重要公告：康希诺重组新型冠状病毒疫苗附条件上市申请获国家药监局受理",
    "href": "http://stock.jrj.com.cn/2021/02/24184032019922.shtml",
    "datetime": "2021-02-24 18:40:14",
    "code": "688185"
  },
  {
    "title": "康希诺：重组新型冠状病毒疫苗附条件上市申请获国家药监局受理",
    "href": "http://stock.jrj.com.cn/2021/02/24181532019812.shtml",
    "datetime": "2021-02-24 18:15:02",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭美国资本集团减持55.5万股",
    "href": "http://stock.jrj.com.cn/2021/02/19072831990421.shtml",
    "datetime": "2021-02-19 07:28:07",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B：预计2020年度净亏损超4亿元人民币",
    "href": "http://stock.jrj.com.cn/2021/02/18162631986914.shtml",
    "datetime": "2021-02-18 16:26:35",
    "code": "688185"
  },
  {
    "title": "游资大买疫苗茅台康希诺 周期股躁动机构疯狂追涨",
    "href": "http://stock.jrj.com.cn/2021/02/18081231984102.shtml",
    "datetime": "2021-02-18 08:12:36",
    "code": "688185"
  },
  {
    "title": "康希诺生物：预计2020年净亏损4亿元到4.3亿元",
    "href": "http://stock.jrj.com.cn/2021/02/17160431974176.shtml",
    "datetime": "2021-02-17 16:04:55",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持20.8万股",
    "href": "http://stock.jrj.com.cn/2021/02/17064331967277.shtml",
    "datetime": "2021-02-17 06:43:24",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)：重组新冠疫苗(腺病毒5型载体)在巴基斯坦获紧急使用授权",
    "href": "http://stock.jrj.com.cn/2021/02/16080331952141.shtml",
    "datetime": "2021-02-16 08:03:25",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获美国资本集团增持25.88万股",
    "href": "http://stock.jrj.com.cn/2021/02/11110731886516.shtml",
    "datetime": "2021-02-11 11:07:21",
    "code": "688185"
  },
  {
    "title": "康希诺新冠疫苗单针重症保护率达90.98% 疫苗概念股集体爆发",
    "href": "http://stock.jrj.com.cn/2021/02/10191931884422.shtml",
    "datetime": "2021-02-10 19:19:56",
    "code": "688185"
  },
  {
    "title": "康希诺AH股齐涨 腺病毒载体疫苗Ad5-nCoV公布三期数据",
    "href": "http://stock.jrj.com.cn/2021/02/09093131875478.shtml",
    "datetime": "2021-02-09 09:31:58",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)遭摩根大通减持35.55万股",
    "href": "http://stock.jrj.com.cn/2021/02/09065831874047.shtml",
    "datetime": "2021-02-09 06:58:40",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B(06185.HK)获摩根大通增持34.3万股",
    "href": "http://stock.jrj.com.cn/2021/02/08065031867327.shtml",
    "datetime": "2021-02-08 06:50:18",
    "code": "688185"
  },
  {
    "title": "康希诺生物-B：重组新冠病毒疫苗成功达到预设的主要有效性及安全性目的",
    "href": "http://stock.jrj.com.cn/2021/02/01180731831413.shtml",
    "datetime": "2021-02-01 18:07:30",
    "code": "688185"
  },
  {
    "title": "康希诺生物预计2020年亏损人民币4-4.3亿元，同比增至少1.5倍",
    "href": "http://stock.jrj.com.cn/2021/01/29143531808931.shtml",
    "datetime": "2021-01-29 14:35:13",
    "code": "688185"
  },
  {
    "title": "亏损预超4亿！康希诺2020年研发费用大幅上升",
    "href": "http://stock.jrj.com.cn/2021/01/29093731807178.shtml",
    "datetime": "2021-01-29 09:37:51",
    "code": "688185"
  },
  {
    "title": "康希诺2020年预计亏损4亿-4.3亿 研发费用大幅上升",
    "href": "http://stock.jrj.com.cn/2021/01/28223431803616.shtml",
    "datetime": "2021-01-28 22:34:47",
    "code": "688185"
  }
]